Agenus Stock Hit Hard by FDA Reaction on BOT/BAL Therapy
Thursday, 18 July 2024, 14:42
Agenus Stock Dives 60% Due to FDA Feedback on BOT/BAL Therapy
The recent FDA feedback on Agenus stock regarding the BOT/BAL therapy has caused a sharp 60% decline in the stock price.
Key Points:
- The stock plunged: Agenus stock experienced a significant 60% drop following the FDA feedback.
- Regulatory impact: The FDA feedback on BOT/BAL therapy has highlighted the influence of regulatory decisions on the biotech sector.
Investors should watch closely: Monitoring Agenus' response to the FDA feedback will be crucial in assessing its future performance.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.